Related Experiment Video
Updated: Jul 6, 2025
Author Spotlight: Ex Vivo OCT-Based Multimodal Imaging of Human Donor Eyes for Research into Age-Related Macular Degeneration
Published on: May 26, 2023
Deferoxamine-related bilateral maculopathy with optical coherence tomography findings
Neslihan Bayraktar Bilen1, Burcu Polat Gültekin2, Simten Dagdas3
1Department of Ophthalmology, Ankara Bilkent City Hospital, Üniversiteler Mahallesi 1604. Cadde No: 9, Gayret Mah. Oruc Reis Sk. Parkciftlik Konutlari CK-6/17, Yenimahalle, Çankaya, Ankara, Turkey.
Background:
We present a case of bilateral maculopathy associated with deferoxamine mesylate (DFO) treatment.
Methods:
A 53-year-old man with myelodysplastic syndrome (MDS) received DFO therapy due to elevated ferritin levels. He was then referred to ophthalmology clinic due to blurred vision. He was diagnosed as bilateral neurosensory retinal detachment of the macula. During follow up, best corrected visual acuity (BCVA), optical coherence tomography (OCT), fundus fluorescein angiography (FFA), and fundus autofluorescence (FAF) were evaluated.
Results:
At first visit, OCT showed bilateral foveal neurosensory detachment. Hyperfluorescence of the macula and the peripapillary region were found on FFA. After discontinuation of DFO, BCVA improved from 20/120 to 20/60 with resolution of the foveal detachments on OCT scan. Four weeks later, FAF showed bilateral mottled hyperautofluorescence and hypoautofluorescence at the macula and the peripapillary region.
Conclusion:
Deferoxamine can cause acute retinal toxicity. Haematologists should be alert to visual complaints associated with DFO therapy, as early diagnosis and discontinuation of the medication allows recovery of visual function with residual fundus findings.
